{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T09:55:38Z","timestamp":1775296538576,"version":"3.50.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,6,1]]},"DOI":"10.1093\/jac\/dki134","type":"journal-article","created":{"date-parts":[[2005,5,5]],"date-time":"2005-05-05T00:25:50Z","timestamp":1115252750000},"page":"944-949","source":"Crossref","is-referenced-by-count":48,"title":["Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control"],"prefix":"10.1093","volume":"55","author":[{"given":"Steven D.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria M.","family":"Traczewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,5,4]]},"reference":[{"key":"key\n\t\t\t\t20171010135248_R1","unstructured":"Brown S, Traczewski M. Doripenem: in vitro potency, spectrum of activity, MIC and disc breakpoints. In: Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract E-2016, p. 175. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171010135248_R2","unstructured":"Traczewski MM, Brown SD. In vitro activity of doripenem versus 194 strains of P. aeruginosa and B. cepacia from both cystic fibrosis and non-cystic fibrosis patients. In: Abstracts of the One Hundred-fourth General Meeting of the American Society for Microbiology, New Orleans, LA, 2004. Abstract A-141, p. 28. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171010135248_R3","doi-asserted-by":"crossref","unstructured":"Tsuji M, Ishii Y, Ohno A et al. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother1998; 42: 94\u20139.","DOI":"10.1128\/AAC.42.1.94"},{"key":"key\n\t\t\t\t20171010135248_R4","doi-asserted-by":"crossref","unstructured":"Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized \u03b2-lactamases. Antimicrob Agents Chemother2004; 48: 1313\u20139.","DOI":"10.1128\/AAC.48.4.1313-1319.2004"},{"key":"key\n\t\t\t\t20171010135248_R5","doi-asserted-by":"crossref","unstructured":"Mikamo H, Izumi K, Hau YZ et al. In vivo and in vivo antibacterial activities of a new injectable carbapenem, S-4664, against gynaecological pathogens. J Antimicrob Chemother2000; 46: 471\u20134.","DOI":"10.1093\/jac\/46.3.471"},{"key":"key\n\t\t\t\t20171010135248_R6","doi-asserted-by":"crossref","unstructured":"Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother2004; 48: 3086\u201392.","DOI":"10.1128\/AAC.48.8.3086-3092.2004"},{"key":"key\n\t\t\t\t20171010135248_R7","doi-asserted-by":"crossref","unstructured":"Ge Y, Wikler MA, Sahm DF et al. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother2004; 48: 1384\u201396.","DOI":"10.1128\/AAC.48.4.1384-1396.2004"},{"key":"key\n\t\t\t\t20171010135248_R8","unstructured":"National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003."},{"key":"key\n\t\t\t\t20171010135248_R9","unstructured":"National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disc Susceptibility Tests: Approved Standard M2-A8. NCCLS, Wayne, PA, USA, 2003."},{"key":"key\n\t\t\t\t20171010135248_R10","unstructured":"National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Approved Standard M11-A6. NCCLS, Wayne, PA, USA, 2004."},{"key":"key\n\t\t\t\t20171010135248_R11","unstructured":"National Committee for Clinical Laboratory Standards. Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters: Approved Standard M23-A2. NCCLS, Wayne, PA, USA, 2001."},{"key":"key\n\t\t\t\t20171010135248_R12","unstructured":"Bhavnani SM, Hammel JP, Cirincione BB et al. PK-PD target attainment with Monte Carlo Simulation (MCS) as decision support of phase 2\/3 dosing strategies for the clinical development of doripenem (DOR). In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract A-11, p. 2. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171010135248_R13","unstructured":"Thye DA, Kilfoil T, Leighton A et al. A Phase 1 study to evaluate safety, tolerability and pharmacokinetics in a western healthy volunteer population. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract A-21, p. 5. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171010135248_R14","unstructured":"Andes DR, Keim S, Craig WA. In vivo pharmacodynamic activity of a new carbapenem, doripenem (DOR), against multiple bacteria in a murine thigh infection model. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract A-309, p. 10. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171010135248_R15","unstructured":"National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Approved Standard M100-S10. NCCLS, Wayne, PA, USA, 1999."},{"key":"key\n\t\t\t\t20171010135248_R16","doi-asserted-by":"crossref","unstructured":"Gavan TL, Jones RN, Barry AL et al. Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disc diffusion susceptibility tests: a collaborative study. J Clin Microbiol1981; 14: 67\u201372.","DOI":"10.1128\/JCM.14.1.67-72.1981"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/55\/6\/944\/2155709\/dki134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T06:48:09Z","timestamp":1586242089000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/55\/6\/944\/725589\/Comparative-in-vitro-antimicrobial-activity-of-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,4]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2005,5,4]]},"published-print":{"date-parts":[[2005,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki134","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,6]]},"published":{"date-parts":[[2005,5,4]]}}}